Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed + Gemcitabine in Extensive-Stage SCLC
NCT00129974Phase 2Terminated
- Sponsor
- Tufts Medical Center
- Start
- Aug 2005
- Primary completion
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in small cell lung cancer (SCLC), sponsored by Tufts Medical Center. Primary endpoint: Response Rate. Started Aug 2005; status: terminated.
02
Drugs
pemetrexed
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00129974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00129974.